Talimogene Laherparepvec: A groundbreaking viral therapy for late stage melanoma: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
<!-- Do not edit this line-->{{Curated}} | <!-- Do not edit this line-->{{Curated}} | ||
== | |||
==Classification== | |||
<b> Baltimore classification: </b> dsDNA <br> | |||
<b> Family: </b> Herpesviridae <br> | |||
<b> Virion: </b> Enveloped <br> | |||
<b> Capsid symmetry: </b> Icosahedral <br> | |||
<b> Replication site: </b>Nucleus and cytoplasm <br> | |||
==Overview of Talimogene Laherparepvev (T-VEC)== | |||
[[ http://darwin.bio.uci.edu/~faculty/wagner/hsvimg02.jpg|thumb|300px|right|<b> Figure 1:</b> <i> </i> <i> </i> | [[ http://darwin.bio.uci.edu/~faculty/wagner/hsvimg02.jpg|thumb|300px|right|<b> Figure 1:</b> <i> </i> <i> </i> | ||
| Line 21: | Line 29: | ||
<br><b>Superscript:</b> Fe<sup>3+</sup> | <br><b>Superscript:</b> Fe<sup>3+</sup> | ||
==Section 2== | ==Section 2== | ||
Revision as of 20:45, 2 April 2018
Classification
Baltimore classification: dsDNA
Family: Herpesviridae
Virion: Enveloped
Capsid symmetry: Icosahedral
Replication site: Nucleus and cytoplasm
Overview of Talimogene Laherparepvev (T-VEC)
[[ http://darwin.bio.uci.edu/~faculty/wagner/hsvimg02.jpg%7Cthumb%7C300px%7Cright%7C Figure 1:
By Alex Fazioli
Talimogene Laherparepvec (T-VEC) is an engineered Herpes simplex virus type 1 designed to specifically target, reproduce, and lyse human tumor cells [1]. T-VEC also produces granulocyte macrophage colony-stimulating factor (GM-CSF) to improve the antitumor immune response within the human body upon the lysis of tumor cells [1]. T-VEC avoids infecting non-cancerous cells by having all copies of two key neurovirulence factor genes deleted RL1 and US12 [2]. The deletion of the US12 gene puts its promoter in close proximity to the US11 increasing its expression which has been shown to increase the ability of T-VEC to replicate within tumour cells [3].
Double brackets: [[
Filename: PHIL_1181_lores.jpg
Thumbnail status: |thumb|
Pixel size: |300px|
Placement on page: |right|
Legend/credit: Electron micrograph of the Ebola Zaire virus. This was the first photo ever taken of the virus, on 10/13/1976. By Dr. F.A. Murphy, now at U.C. Davis, then at the CDC.
Closed double brackets: ]]
Other examples:
Bold
Italic
Subscript: H2O
Superscript: Fe3+
Section 2
Include some current research, with at least one figure showing data.
Section 3
Include some current research, with at least one figure showing data.
Section 4
Conclusion
References
1. Andtbacka, R. H., Kaufman, H. L., Collichio, F., Amatruda, T., Senzer, N., Chesney, J., ... & Milhem, M. (2015). Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. Journal of clinical oncology, 33(25), 2780-2788.
2. Pol, J., Kroemer, G., & Galluzzi, L. (2016). First oncolytic virus approved for melanoma immunotherapy.
3. Liu, B. L., Robinson, M., Han, Z., Branston, R. H., English, C., Reay, P., & ... Coffin, R. S. (2003). ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Therapy, 10(4), 292.
Authored for BIOL 238 Microbiology, taught by Joan Slonczewski, 2018, Kenyon College.
